Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been given a consensus rating of “Buy” by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $9.50.

A number of research firms have issued reports on QNCX. Maxim Group initiated coverage on Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 target price on the stock. Brookline Capital Management started coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. Finally, D. Boral Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Quince Therapeutics in a research report on Wednesday, February 5th.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Shay Capital LLC grew its stake in shares of Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after acquiring an additional 104,616 shares during the period. Scharf Investments LLC bought a new position in Quince Therapeutics during the fourth quarter worth about $170,000. Geode Capital Management LLC increased its stake in shares of Quince Therapeutics by 24.2% in the third quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after purchasing an additional 66,170 shares in the last quarter. Two Sigma Investments LP bought a new stake in shares of Quince Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Virtu Financial LLC bought a new position in Quince Therapeutics in the 4th quarter worth approximately $55,000. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $1.39 on Friday. The company has a market cap of $61.16 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a fifty day moving average price of $1.63 and a 200-day moving average price of $1.34.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.